Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer.
Ruiz
Nuria
N
Instituto Valenciano de Oncologia, Valencia, Spain.
Fernandez-Martos
Carlos
C
Romero
Ignacio
I
Pla
Angel
A
Maiquez
Joaquin
J
Calatrava
Ana
A
Guillem
Vicente
V
D000230:Adenocarcinoma / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003110:Colonic Neoplasms / Q000188:drug therapy*; D005670:Fusarium / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000139:chemically induced*; D009300:Nasal Septum / Q000382:microbiology*; D009668:Nose Diseases / Q000382:microbiology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab